|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
| ||||||||||||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
V-Sciences Investments Pte Ltd 60B ORCHARD ROAD #06-18, TOWER 2 THE ATRIUM@ORCHARD SINGAPORE, U0 238891 |
X | |||
Temasek Life Sciences Private LTD 60B ORCHARD ROAD #06-18, TOWER 2 THE ATRIUM@ORCHARD SINGAPORE, U0 238891 |
X | |||
Fullerton Management Pte Ltd 60B ORCHARD ROAD #06-18, TOWER 2 THE ATRIUM@ORCHARD SINGAPORE, U0 238891 |
X | |||
TEMASEK HOLDINGS (PRIVATE) LTD 60B ORCHARD ROAD #06T-18, TOWER 2 THE ATRIUM@ORCHARD SINGAPORE, U0 238891 |
X |
/s/ Lena Chia Yue Joo, Managing Director, Legal & Regulations, Temasek Holdings (Private) Limited | 04/30/2009 | |
**Signature of Reporting Person | Date | |
/s/ Cheo Hock Kuan, Director, Temasek Life Sciences Private Limited | 04/30/2009 | |
**Signature of Reporting Person | Date | |
/s/ Lena Chia Yue Joo, Director, Fullerton Management Pte Ltd | 04/30/2009 | |
**Signature of Reporting Person | Date | |
/s/ Choo Soo Shen Christina, Director, V-Sciences Investments Pte Ltd | 04/30/2009 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | Represents the weighted average price of 451 different transactions. Actual sale prices ranged from $2.32 to $2.90 per share. The reporting person will provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, information regarding the number of shares of common stock, $0.01 par value per share, which are the subject of this filing (the "Shares"), sold at each price within the range. |
(2) | Temasek Holdings (Private) Limited, is the parent of Fullerton Management Pte Ltd, which is the parent of Temasek Life Sciences Private Limited, which is the parent of V-Sciences Investments Pte Ltd (the designated filer), which directly owns the Shares. Because of the foregoing relationships, the direct and indirect parents of V-Sciences Investments Pte Ltd may be deemed to beneficially own the Shares. |
(3) | Represents the weighted average price of 271 different transactions. Actual sale prices ranged from $2.17 to $2.51 per share. The reporting person will provide to the issuer, any shareholder of the issuer, or the Staff, upon request, information regarding the number of Shares sold at each price within the range. |